NIS2+™作为筛选工具优化代谢功能障碍相关脂肪性肝炎临床试验中的患者选择
在RESOLVE-IT试验的筛查路径队列中进行回顾性模拟分析,纳入1929例患者,765例(40%)为高危MASH。使用成本优化界值(NIS2+™ 0.53;FIB-4 0.58)时,NIS2+™路径的肝活检失败率(39%)显著低于FIB-4路径(58%)或RSP(60%)。每1000例入组,NIS2+™较RSP显著减少不必要的肝活检(632 vs 1522;
要点
- NIS2+™路径肝活检失败率39%,低于FIB-4路径58%和RSP 60%。
- 每1000例入组,NIS2+™较RSP减少不必要肝活检632 vs 1522(-58%)。
核心结论
- 使用NIS2+™选择患者进行肝活检可显著减少不必要的活检和筛查成本,可能大幅提高MASH临床试验的可行性。
研究设计与样本
- 在RESOLVE-IT临床试验(NCT02704403)筛查路径(RSP)队列中进行的回顾性模拟分析,分析队列纳入1929例患者。
主要发现
- 分析队列1929例患者中765例(40%)为高危MASH。
- 使用成本优化界值(NIS2+™ 0.53;FIB-4 0.58)时,NIS2+™路径肝活检失败率39%,显著低于FIB-4路径58%或RSP 60%。
- 单独NIS2+™优于单独FIB-4或联合FIB-4。
- 基于组织学、性别、年龄或合并症的分析未显示招募偏倚。
关键数值与推荐
- 高危MASH定义为MASH合并代谢功能障碍相关脂肪性肝病评分≥4且纤维化分期≥2。
- 成本优化界值:NIS2+™ 0.53;FIB-4 0.58。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect "at-risk" metabolic dysfunction-associated steatohepatitis (MASH; MASH with metabolic dysfunction-associated steatotic liver disease score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® technology designed to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for optimized selection of patients for LB. METHODS: A retrospective simulation analysis was conducted in the RESOLVE-IT screening pathway (RSP) cohort. LB failure rate (LBFR), number of patients needed to screen, and overall cost estimations of different pathways were calculated for a range of NIS2+™ and FIB-4 cut-offs and compared with those of the RSP, which relied on investigators' local practices. An analysis of potential recruitment bias based on histology, sex, age, or comorbidities was performed. RESULTS: The analysis cohort included 1,929 patients, 765 (40%) with at-risk MASH. The NIS2+™ pathway resulted in a significantly lower LBFR (39%) compared with the FIB-4 pathway (58%) or the RSP (60%) when using cost-optimized cut-offs (NIS2+™, 0.53; FIB-4, 0.58). For every 1,000 inclusions, NIS2+™ significantly reduced unnecessary LBs (632 vs. 1,522; -58%) and screening costs (US$12.7 million vs. US$15.0 million) vs. the RSP, while the number of patients needed to screen increased moderately (3,220 to 4,033). NIS2+™ alone is better than FIB-4 alone or combined with FIB-4. CONCLUSIONS: This analysis demonstrated that patient selection for LB using NIS2+™ significantly reduced unnecessary biopsies and screening costs, which could greatly improve the feasibility of MASH clinical trials. IMPACT AND IMPLICATIONS: Simple and accurate non-invasive strategies to optimize the selection of patients who should be referred for liver biopsy for inclusion in MASH clinical trials is critical to reduce the high liver biopsy failure rates. While the use of the Fibrosis-4 index alone did not lead to a significant improvement of the screening process, selecting patients using NIS2+™, a recently developed optimization of the NIS4® technology for the detection of at-risk MASH, showed improved performance by simultaneously reducing liver biopsy failure rates and the overall cost of the trial, while maintaining the number of patients needed to screen at a manageable level and not generating any bias in included patients' characteristics. This makes NIS2+™ an accurate and reliable screening tool that could improve the recruitment of patients in future MASH clinical trials, and would lead to increased patient comfort and security, ensuring timely and cost-efficient trial completion.
引用
- Ratziu V, Harrison SA, Hajji Y, et al. NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials. J Hepatol. 2023. PMID: 38061448. doi:10.1016/j.jhep.2023.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。